Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
 - EconoTimes)
NEW ORLEANS, May 14, 2017 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (Nasdaq:AKTX), if they purchased the Company’s securities between March 30, 2017, and May 11, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
What You May Do
If you purchased securities of Akari Therapeutics and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by July 11, 2017.
About the Lawsuit
Akari Therapeutics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company’s CEO, and possibly others, caused false information about the Company to be published, including but not limited to, false information regarding the Phase 2 PNH trial of Coversin; (ii) the Company lacked adequate measures to prevent such behavior; and (iii) as a result of the foregoing, Akari Therapeutics’ financial statements were materially false and misleading at all relevant times.
On this news, the price of Akari Therapeutics’ shares plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
